SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chiong, J. R
Right arrow Articles by Miller, A. B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiong, J. R
Right arrow Articles by Miller, A. B
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management

Jun R Chiong

University of Florida, Health Science Center, 655 W 8th Street, Jacksonville, FL 32209, USA, jun.chiong@ jax.ufl.edu

Alan B Miller

University of Florida, Health Science Center, 655 W 8th Street, Jacksonville, FL 32209, USA

The renin-angiotensin system (RAS) and dyslipidaemia have been shown to be involved in the genesis and progression of atherosclerosis. Manipulation of the RAS has been effective in modifying human coronary artery disease progression. Similarly, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors or `statins' have been shown to reduce cholesterol and lower cardiovascular events in primary and secondary prevention trials in coronary artery disease. In addition to their primary mode of action, statins and blockers of the RAS possess common additional properties that include restoration of endothelial activity and inhibition of cellular proliferation. This article reviews the current data on the common properties of these classes of drugs in which the beneficial effects extend beyond their antihypertensive and lipid-lowering properties.

Key Words: renin-angiotensin system • atherosclerosis • angiotensin-converting enzyme inhibitors • angiotensin receptor blockers • statins

References

  • Ferrario CM Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002;15:9S-13S.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The pooling project research group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978;31:201-306.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Samuelsson O., Wilhelmsen L., Andersson OK, Pennert K., Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, Sweden.JAMA 1987;258:1768-76.
  • Luscher TF Endothelial dysfunction in atherosclerosis. J Myocard Ischemia 1995;7(suppl 1):15-20.
  • Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine.A paradigm shift? Circulation 1994;89:493-8.[Free Full Text]
  • Dzau VJ Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59:59A-65A.[CrossRef][Medline] [Order article via Infotrieve]
  • Diet F., Pratt RE, Berry GJ, Momose N., Gibbons GH, Dzau VJ Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.[Abstract/Free Full Text]
  • Dzau VJ Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994;128:1300-04.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Reilly M., Delanty N., Lawson JA, FitzGerald GA Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19-25.[Abstract/Free Full Text]
  • Vita JA, Treasure CB, Nabel EG et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7.[Abstract/Free Full Text]
  • Tsurumi Y., Nagashima H., Ichikawa K., Sumiyoshi T.,Hosoda S. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 1995;26: 1242-50.[Abstract]
  • Rubanyi GM The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22 (suppl 4):S1-14.
  • Inagami T., Iwai N., Sasaki K. et al. Cloning, expression and regulation of angiotensin II receptors. Eur Heart J 1994;15(suppl D):104-07.[Abstract/Free Full Text]
  • Berk BC, Vekshtein V., Gordon HM,TsudaT. Angiotensin IIstimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-14.[Abstract/Free Full Text]
  • Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.[Abstract/Free Full Text]
  • Schmieder RE, Langenfeld MR, Friedrich A., Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996;94:1304-9.[Abstract/Free Full Text]
  • Harrap SB, Dominiczak AF, Fraser R. et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-54.[Abstract/Free Full Text]
  • Jacobi J., Schlaich MP, Delles C., Schobel HP, Schmieder RE Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999;12:418-22.[Web of Science][Medline] [Order article via Infotrieve]
  • Powell JS, Clozel JP, Muller RK et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.[Abstract/Free Full Text]
  • Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998;98:800-7.[Abstract/Free Full Text]
  • Aviram M., Rosenblat M. Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J Lipid Res 1994;35:385-98.[Abstract]
  • Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • Deslypere JP Modified lipoproteins in diabetes. J Intern Med 1994;736:69-74.
  • Li D., Yang B., Philips MI, Mehta JL Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation.AmJPhysiol 1999;276:H786-92.[Web of Science][Medline] [Order article via Infotrieve]
  • Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815-26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sniderman AD, Pedersen T., Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol 1997;79:64-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993;98:1-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Regnstrom J., Nilsson J., Tornvall P., Landou C., Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nickenig G., Jung O., Strehlow K. et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am JPhysiol 1997;272:H2701-07.[Web of Science][Medline] [Order article via Infotrieve]
  • Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993;362:801-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Beisiegel U.Lipoprotein metabolism. Eur Heart J 1998;19 (suppl A):A20-3.[Web of Science][Medline] [Order article via Infotrieve]
  • Hajjar DP, Haberland ME Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975-8.[Free Full Text]
  • Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74: 1141-8.[Abstract/Free Full Text]
  • Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90:1248-53.[Web of Science][Medline] [Order article via Infotrieve]
  • Laufs U., La Fata V., Plutzky J., Liao JK Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.[Abstract/Free Full Text]
  • Castelli WP, Garrison RJ,Wilson PW, Abbott RD, Kalousdian S., Kannel WB Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.[Abstract/Free Full Text]
  • Ichiki T., Takeda K., Tokunou T. et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21:1896-901.[Abstract/Free Full Text]
  • Li DY, Zhang YC, Philips MI, Sawamura T., Mehta JL Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999;84:1043-9.[Abstract/Free Full Text]
  • Morawietz H., Rueckschloss U., Niemann B. et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999;100: 899-902.[Abstract/Free Full Text]
  • Gibbons GH, Pratt RE, Dzau VJ Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-61.[Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S., Pepine CJ, Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rutherford JD, Pfeffer MA, Moye LA et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-8.[Abstract/Free Full Text]
  • Pfeffer MA, Braunwald E., Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.[Abstract]
  • Kober L., Torp-Pedersen C., Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. NEnglJMed 1995;333:1670-6.[Abstract/Free Full Text]
  • The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.NEnglJMed 1995;332:80-5.[Abstract/Free Full Text]
  • Finta KM, Fischer MJ, Lee L., Gordon D., Pitt B., Webb RC Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet.Atherosclerosis 1993;100:149-56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mancini GB, Henry GC, Macaya C. et al.Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65.[Abstract/Free Full Text]
  • Lee AF, Dick JB, Bonnar CE, Struthers AD Lisinopril improves arterial function in hyperlipidaemia. Clin Sci 1999;96:441-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Prasad A., Husain S., Quyyumi AA Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol 1999;84:1-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Anderson TJ, Elstein E., Haber H., Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.[Abstract/Free Full Text]
  • Chobanian AV, Haudenschild CC, Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.[Abstract/Free Full Text]
  • Dzau VJ Tissue angiotensin and pathobiology of vascular disease. Hypertension 2001;37:1047-52.[Abstract/Free Full Text]
  • Johnston CI, Mendelsohn FA, Cubela RB, Jackson B., Kohzuki M., Fabris B. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors. J Hypertens 1988;6:S17-22.[Web of Science]
  • Lonn E., Yusuf S., Dzavik V. et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.[Abstract/Free Full Text]
  • Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mathew J., Sleight P., Lonn E. et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.[Abstract/Free Full Text]
  • de Gasparo M., Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 1998;82:257-71.[Web of Science][Medline] [Order article via Infotrieve]
  • Jalowy A., Schulz R., Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 1999;10(suppl 11):S129-36.[Web of Science][Medline] [Order article via Infotrieve]
  • Israili ZH Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14 (suppl 1):S73-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Corea L., Cardoni O., Fogari R. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Black HR, Graff A., Shute D. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Benz J., Oshrain C., Henry D., Avery C., Chiang YT, Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a doubleblind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-07.[Abstract]
  • Elliott WJ Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J Hum Hypertens 1999;13:413-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Larochelle P., Flack JM, Marbury TC, Sareli P., Krieger EM, Reeves RA Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol 1997;80:1613-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malmqvist K., Kahan T., Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000;13:504-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998;15:229-40.[Web of Science]
  • Granger CB, Ertl G., Kuch J. et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000;139:609-17.[Web of Science][Medline] [Order article via Infotrieve]
  • Katsumata U., Sekizawa K., Ujiie Y., Sasaki H., Takishima T. Bradykinin-induced cough reflex markedly increases in patients with cough associated with captopril and enalapril. Tohoku J Exp Med 1991;164:103-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nussberger J., Cugno M.,Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Prasad A., Halcox JP, Waclawiw MA, QuyyumiAA Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol 2001;38:1089-95.[Abstract/Free Full Text]
  • Navalkar S., Parthasarathy S., Santanam N., Khan BV Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001;37:440-4.[Abstract/Free Full Text]
  • Chen H., Li D., Sawamura T., Inoue K., Mehta JL Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 2000; 276:1100-04.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schwemmer M., Sommer O., Bassenge E. Blockade of angiotensin signaling improves myocardial function in hypercholesterolemia independent of changes in eicosanoid release. Cardiovasc Drugs Ther 2000;14:317-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schiffrin EL, Park JB, Intengan HD, Touyz RM Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-9.[Abstract/Free Full Text]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Swedberg K., Pfeffer M., Granger C. et al. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.J Card Fail 1999;5:276-82.[CrossRef][Medline] [Order article via Infotrieve]
  • Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN,Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • The Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shepherd J., Cobbe SM, Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-07.[Abstract/Free Full Text]
  • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl JMed 1998;339:1349-57.[Abstract/Free Full Text]
  • Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-09.[Abstract/Free Full Text]
  • Chen L., Haught WH,Yang B., Saldeen TG, Parathasarathy S., Mehta JL Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997;30:569-75.[Abstract]
  • Benetos A., Safar M., Rudnichi A. et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population.Hypertension 1997;30:1410-15.[Abstract/Free Full Text]
  • Stroes E., de Bruin T., de Valk H. et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc Res 1997;36:445-52.[Abstract/Free Full Text]
  • Lewis TV, Cooper BA, Dart AM, Chin-Dusting JP Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol 1998;124:222-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • O'Driscoll G., Green D., Taylor RR Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.[Abstract/Free Full Text]
  • Heeschen C., Hamm CW, Laufs U., Snapinn S., Bohm M., White HD Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.[Abstract/Free Full Text]
  • Schwartz GG, Oliver MF, Ezekowitz MD et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • Fedder DO, Koro CE, L'Italien GJ New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-6.[Abstract/Free Full Text]
  • Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998;63:1-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rachmani R., Lidar M., Brosh D., Levi Z., Ravid M. Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over study. Diabetes Res Clin Pract 2000; 48:139-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hanefeld M., Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29:270-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-9,A8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-09. 100. Gotto AM Jr, Boccuzzi SJ, Cook JR et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. Am J Cardiol 2000;86:1176-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wright JT Jr. Clinical Trials: new findings from completed studies and future directions. AmJHypertens 1995;8:27A.
  • Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).ALLHAT Research Group. Am J Hypertens 1996;9:342-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Diercks GF, Janssen WM, van Boven AJ et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000;86:635-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 2, 96-102 (2002)
DOI: 10.3317/jraas.2002.024
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chiong, J. R
Right arrow Articles by Miller, A. B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiong, J. R
Right arrow Articles by Miller, A. B
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement